Summary
Eli Lilly has become the first pharmaceutical company to reach a $1 trillion market value. This growth is mainly due to the popularity of its weight-loss drugs, which have driven its stock up by more than 35% this year. The company now has a major share in the obesity treatment market and continues to grow with new drug developments.
Key Facts
- Eli Lilly's market value reached $1 trillion, a first in the pharma industry.
- The company's stock increased over 35% this year, driven by its weight-loss drugs.
- Lilly's popular drugs, Mounjaro and Zepbound, have overtaken competitors in prescriptions.
- Lilly's shares hit a record high of $1,057.70 each.
- The company trades at about 50 times its expected earnings over the next 12 months.
- Revenue from Lilly's obesity and diabetes drugs was $10.09 billion last quarter, more than half of its total $17.6 billion revenue.
- The weight-loss drug market could be worth $150 billion by 2030, with Lilly and Novo Nordisk holding a large market share.
- Investors and analysts are watching Lilly's future growth as it develops new drugs and faces pricing pressures.
